California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
